http://rdf.ncbi.nlm.nih.gov/pubchem/patent/KR-101120130-B1
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K1-18 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K1-22 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K1-32 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-61 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K1-18 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K1-22 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-61 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K1-32 |
| filingDate | 2003-09-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2012-04-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2012-04-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | KR-101120130-B1 |
| titleOfInvention | Process for Reducing Aggregate Levels of Pigmented Proteins |
| abstract | As mentioned above, recombinant PEGylated polypeptide growth hormone agonists, recombinant PEGylated polypeptide human growth hormone agonists, recombinant PEGylated polypeptide growth hormone antagonists and / or comprise reduced levels of undesirable aggregates and / or isomeric impurities. In connection with the need for improved methods of preparing recombinant PEGylated polypeptide human growth hormone antagonists, the present invention provides recombinant PEGylated polypeptide growth hormone (human) comprising reduced levels of aggregates, de- and / or trisulfide isomeric impurities. Provided are improved methods for the production of growth hormone including, but not limited to, and recombinant PEGylated polypeptide growth hormone antagonists (including but not limited to human growth hormone antagonists).n n n With respect to the recombinant growth hormone (including hGH, but is not limited to): (1) a chelating agent (chelating agent), or (2) to the growth hormone, as well the addition of metal salt (metal salt), respectively It is possible to reduce the formation of -isomeric impurities.n n n With respect to the recombinant growth hormone antagonist (including but not limited to human growth hormone antagonist), (1) mercapto compound, (2) chelating agent, (3) metal salt, ( 4) the trisulfide isomeric impurity can be reduced by bringing the mercapto compound together with the metal salt together or (5) the chelating agent and then contacting the mercapto compound with the trisulfide isomeric impurity, respectively, in the absence of the chelating agent. Can be.n n n With respect to the recombinant growth hormone antagonist (including but not limited to human growth hormone antagonist), the de-prop of the growth hormone antagonist may be achieved by adding (1) chelating agent or (2) metal salt, respectively. It is possible to reduce the formation of isomeric impurities.n n n In connection with the recombinant PEGylated protein (including but not limited to PEGylated hormone, PEGylated growth hormone antagonist, PEGylated human growth hormone antagonist, PEGylated growth hormone and / or PEGylated human growth hormone) The level of aggregates is maintained or reduced to or below the desired level by anion exchange chromatography during the separation of PEGylated isomers. |
| priorityDate | 2002-09-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 390.